Why Is Arcturus Therapeutics Stock Trading Higher On Tuesday? - Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.

Related Keywords

Juergen Froehlich ,Joseph Payne ,William Blair ,Vertex Pharmaceuticals Incorporated ,Arcturus Therapeutics Holdings Inc ,Arcturus Therapeutics Holdings ,Cystic Fibrosis ,Forced Expiratory Volume ,Chief Medical Officer ,